反応式
C(N(CC)CC)C.[NH2:8][C@@H:9]1[CH2:15][CH2:14][CH:13]([C:16]2[CH:21]=[CH:20][C:19]([OH:22])=[CH:18][CH:17]=2)[CH2:12][NH:11][C:10]1=[O:23].Cl[C:25](OC1C=CC([N+]([O-])=O)=CC=1)=[O:26].Cl.Cl.[O:39]=[C:40]1[NH:48][C:43]2=[N:44][CH:45]=[CH:46][CH:47]=[C:42]2[N:41]1[CH:49]1[CH2:54][CH2:53][NH:52][CH2:51][CH2:50]1.C(N(C(C)C)CC)(C)C>CN(C)C=O.O1CCCC1>[OH:22][C:19]1[CH:20]=[CH:21][C:16]([CH:13]2[CH2:12][NH:11][C:10](=[O:23])[C@H:9]([NH:8][C:25]([N:52]3[CH2:53][CH2:54][CH:49]([N:41]4[C:42]5[C:43](=[N:44][CH:45]=[CH:46][CH:47]=5)[NH:48][C:40]4=[O:39])[CH2:50][CH2:51]3)=[O:26])[CH2:15][CH2:14]2)=[CH:17][CH:18]=1参加物
8
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
Triethylamine (0.009 mL, 0.091 mmol) was added to a solution of (3R)-3-amino-6-(4-hydroxyphenyl)azepan-2-one (10 mg, 0.045 mmol) and 4-nitrophenyl chloroformate (18 mg, 0.091 mmol) in N,N-dimethylformamide (0.2 mL) and tetrahydrofuran (0.2 mL) at 0° C. After 1 h, 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride (26 mg, 0.091 mmol) and diisopropylethylamine (0.032 mL, 0.182 mmol) were added and the mixture was allowed to warm to ambient temperature. After 18 h, the mixture was purified by reverse phase HPLC (C-18, 95% water/acetonitrile→5% water/acetonitrile with 0.1% trifluoroacetic acid) to give the title compound (7 mg). MS 465.2243 (M+1).
後処理
- waitAfter 18 h
- customthe mixture was purified by reverse phase HPLC (C-18, 95% water/acetonitrile→5% water/acetonitrile with 0.1% trifluoroacetic acid)
出典と根拠
- ORDレコード
- ord-621e893a35514415a8c589a41f9e90ae
- 出典データセット
- uspto-grants-2011_02
- 特許番号
- US07893052B2
関連ノート
読み込み中…